These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 7813808)

  • 1. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 is a physiological incretin in rat.
    Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
    J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
    J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
    Fehmann HC; Göke R; Göke B; Bächle R; Wagner B; Arnold R
    Biochim Biophys Acta; 1991 Feb; 1091(3):356-63. PubMed ID: 1705823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
    Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
    Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
    Wang JH; Inoue T; Higashiyama M; Guth PH; Engel E; Kaunitz JD; Akiba Y
    J Pharmacol Exp Ther; 2011 Nov; 339(2):464-73. PubMed ID: 21846840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
    Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
    J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG; Pittner R; Jodka C; Smith P; Young A
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.
    Herrmann C; Göke R; Richter G; Fehmann HC; Arnold R; Göke B
    Digestion; 1995; 56(2):117-26. PubMed ID: 7750665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew).
    Chan SW; Lin G; Yew DT; Rudd JA
    Eur J Pharmacol; 2011 Oct; 668(1-2):340-6. PubMed ID: 21756894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.
    Edwards CM; Todd JF; Mahmoudi M; Wang Z; Wang RM; Ghatei MA; Bloom SR
    Diabetes; 1999 Jan; 48(1):86-93. PubMed ID: 9892226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that glucagon stimulates insulin secretion through its own receptor in rats.
    Kawai K; Yokota C; Ohashi S; Watanabe Y; Yamashita K
    Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of GIP and GLP-1 antagonists on insulin release in the rat.
    Tseng CC; Zhang XY; Wolfe MM
    Am J Physiol; 1999 Jun; 276(6):E1049-54. PubMed ID: 10362617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate.
    Lavin JH; Wittert GA; Andrews J; Yeap B; Wishart JM; Morris HA; Morley JE; Horowitz M; Read NW
    Am J Clin Nutr; 1998 Sep; 68(3):591-8. PubMed ID: 9734735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
    Luque MA; González N; Márquez L; Acitores A; Redondo A; Morales M; Valverde I; Villanueva-Peñacarrillo ML
    J Endocrinol; 2002 Jun; 173(3):465-73. PubMed ID: 12065236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B; Hughes TE
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.